Accelerate Preclinical IBD Research with Our Intestine-on-a-Chip Model

Our Intestine-on-a-Chip Model is an advanced microphysiological platform designed to recreate key aspects of human intestinal physiology and inflammation under controlled microfluidic conditions. By integrating human intestinal cells, physiologically relevant flow, and mechanical stimulation, this platform provides a powerful tool for studying intestinal barrier dysfunction, immune responses, and therapeutic efficacy in IBD.

This downloadable case study demonstrates how an intestine-on-a-chip system can be used to model IBD-associated inflammation, evaluate disease-relevant endpoints, and generate translational data to support drug discovery and development.

What This Case Study Shows

In this study, a human-relevant intestine-on-a-chip platform was used to reconstruct an inflammatory intestinal microenvironment and evaluate therapeutic intervention under dynamic culture conditions. A comprehensive panel of functional, molecular, and cellular readouts was employed to characterize disease progression and treatment response, including:

• Epithelial Barrier Function Assessment
  Evaluation of barrier integrity through TEER measurements, permeability analysis, and tight junction protein characterization to monitor epithelial dysfunction and recovery.
• Inflammatory Response Profiling
  Quantification of inflammatory mediators and immune-related biomarkers to assess disease severity and pharmacological activity.
• Immune Cell Analysis
  Assessment of immune cell activation and macrophage polarization to investigate intestinal immune responses and therapeutic mechanisms of action.
• Structural and Morphological Characterization
  Immunofluorescence imaging and microscopic analyses to visualize epithelial organization, cellular interactions, and barrier integrity under inflammatory conditions.

Download the Case Study

Discover how our Intestine-on-a-Chip Model can help generate more predictive efficacy data, improve translational confidence, and accelerate the development of next-generation therapies for inflammatory bowel disease.

You might be interested in...